Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics SARASOTA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE: OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today announced the conversion of its remaining outstanding convertible Series A and Series B Preferred Shares into common stock. The conversion helps simplify the company’s capital structure and eliminates approximately $2.35 million…